Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATARAX vs ACUVUE THERAVISION WITH KETOTIFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Hydroxyzine is a piperazine derivative with antihistaminic (H1-receptor antagonist) and anticholinergic properties; also exhibits sedative, anxiolytic, and antiemetic effects due to suppression of activity in subcortical areas of the CNS.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Pruritus due to allergic conditions (FDA approved),Anxiety and tension (FDA approved for psychoneurosis),Sedation before and after general anesthesia (FDA approved),Off-label: Nausea and vomiting, motion sickness, insomnia
FDA-approved for the prevention and treatment of ocular itching associated with allergic conjunctivitis
25 mg orally 3-4 times daily; maximum 100 mg per day. Also available as 50 mg intramuscular injection every 4-6 hours.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly, hepatic impairment, or renal insufficiency (up to 30-40 hours); steady-state achieved within 3-4 days.
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Primarily hepatic via CYP3A4 and CYP2D6; major metabolite is cetirizine.
Not significantly metabolized in the eye; systemic absorption is minimal. After systemic absorption, it is metabolized primarily via glucuronidation and oxidation, with a half-life of approximately 12 hours.
Primarily hepatic metabolism via CYP3A4 and CYP2D6; renal excretion of metabolites accounts for approximately 70-80% of the dose, with less than 1% excreted unchanged; fecal excretion is about 10-15%.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Approximately 93% bound primarily to albumin and alpha-1-acid glycoprotein.
99% (primarily albumin and alpha-1-acid glycoprotein).
Approximately 10-15 L/kg; large Vd indicates extensive tissue distribution, including penetration into the central nervous system.
2.4 L/kg (high tissue distribution, including ocular tissues).
Oral bioavailability is approximately 100% (nearly complete absorption) with peak plasma concentrations at 2 hours; intramuscular bioavailability is similar to oral but with faster absorption.
Ocular topical: ~0.1% systemic; oral: 70% (not relevant for contact lens application).
GFR 10-50 m L/min: administer every 24 hours. GFR <10 m L/min: contraindicated or reduce dose to 50% every 24 hours.
No dosage adjustment required based on renal function; systemic absorption is minimal.
Child-Pugh Class A: no adjustment. Class B: reduce dose by 50%. Class C: contraindicated.
No dosage adjustment required based on hepatic function; systemic absorption is minimal.
Children >6 years: 0.6 mg/kg orally every 6 hours; maximum 2 mg/kg/day. Children <6 years: 0.5 mg/kg orally every 4-6 hours; maximum 50 mg/day.
Safety and efficacy in pediatric patients below 3 years of age have not been established. For children 3 years and older, administer one drop in each affected eye twice daily.
Initiate at 12.5 mg orally twice daily; may increase gradually. Avoid use in patients with significant renal impairment or dementia due to anticholinergic effects.
No specific dosage adjustment is required for elderly patients; use same dosing as for adults.
Not applicable; no black box warning.
None
Drowsiness and impairment of alertness; avoid driving or operating machinery,Potentiation of CNS depressants (alcohol, barbiturates, opioids),Anticholinergic effects (urinary retention, blurred vision, constipation),QT prolongation risk (especially with electrolyte disturbances, pre-existing QT prolongation, or concurrent QT-prolonging drugs),Use with caution in elderly due to increased risk of sedation and falls,Tardive dyskinesia with prolonged high-dose use
For topical ophthalmic use only; not for injection.,Contains benzalkonium chloride; soft contact lens wearers should remove lenses before application and wait at least 10 minutes before reinserting.,May cause transient stinging or burning upon instillation.,Use with caution in patients with known hypersensitivity to any component.
Hypersensitivity to hydroxyzine or any component of the formulation,Early pregnancy (first trimester) due to potential fetal harm,Porphyria,Lactation (excreted in breast milk)
Hypersensitivity to ketotifen or any component of the product.
No significant food interactions reported. However, alcohol should be avoided due to additive CNS depression. Grapefruit juice may theoretically increase hydroxyzine levels via CYP3A4 inhibition, but clinical significance is minimal; caution is advised.
None reported.
First trimester: Considered safe; large studies show no increased risk of major malformations. Second trimester: No known specific risks. Third trimester: Use near term may cause neonatal withdrawal or CNS depression (drowsiness, irritability, tremors) due to placental transfer.
Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenicity at doses up to 50 mg/kg/day orally. Risk to fetus is considered low when used topically as directed.
Atarax (hydroxyzine) is excreted into breast milk in small amounts; M/P ratio approximately 0.7. Use with caution; monitor infant for sedation, irritability, or feeding difficulties. The American Academy of Pediatrics considers it compatible with breastfeeding, but alternative agents may be preferred.
Ketotifen is excreted in human milk following oral administration; however, systemic absorption from ophthalmic use is negligible. M/P ratio not established for ophthalmic route. Consider benefit vs risk; caution in breastfeeding mothers.
No dose adjustment is typically required for non-sedating use. However, pharmacokinetic changes in pregnancy (increased plasma volume, altered clearance) may necessitate cautious titration; start at lowest effective dose and adjust based on clinical response. For severe pruritus in pregnancy, typical adult dosing (25 mg tid or qid) is used, but monitor for excessive sedation.
No dosage adjustment required. Use as directed; pharmacokinetic changes in pregnancy are not significant for topical ophthalmic route.
ATARAX (hydroxyzine) is a first-generation antihistamine with anxiolytic and sedative properties. It is commonly used for pruritus, anxiety, and preoperative sedation. Note: QT prolongation risk at high doses; avoid in patients with known QT interval prolongation or concurrent use of other QT-prolonging agents. Onset of sedation is rapid, making it useful for sleep induction, but tolerance develops with chronic use. Anticholinergic effects (dry mouth, urinary retention) are dose-dependent.
Ketotifen is a mast cell stabilizer and antihistamine; contact lens must be removed before instillation and may be reinserted after 10 minutes. Do not use while wearing contact lenses. Advise patient to wait at least 5 minutes between different eye drops. The preservative benzalkonium chloride may be absorbed by soft contact lenses.
Take exactly as prescribed; do not exceed recommended dose.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase drowsiness and dizziness.,Do not drive or operate heavy machinery until you know how this medication affects you.,Report any signs of allergic reaction (rash, difficulty breathing) or irregular heartbeat (palpitations, syncope) immediately.,Hydrate adequately to reduce dry mouth; sugar-free gum or candy can help.,Do not discontinue abruptly; follow your doctor's instructions for tapering if needed.
Remove contact lenses before using the drops and wait at least 10 minutes before reinserting.,Wash hands before use. Do not touch the dropper tip to any surface, including the eye.,Do not use if the solution changes color or becomes cloudy.,Use exactly as prescribed; do not use more often than directed.,If you miss a dose, use it as soon as possible. If it is almost time for the next dose, skip the missed dose and resume your regular schedule. Do not double the dose.,Contact your doctor if you experience eye pain, vision changes, or if symptoms persist or worsen.
No interactions on record
"Lisdexamfetamine, a prodrug of dextroamphetamine, increases central nervous system (CNS) arousal via dopamine and norepinephrine release, counteracting the sedative effects of ketotifen, a mast cell stabilizer with histamine H1-receptor antagonism and CNS depressant properties. The interaction results in reduced sedative efficacy of ketotifen, potentially affecting therapeutic outcomes in allergic conditions where sedation is beneficial, such as severe pruritus or urticaria. Clinically, patients may experience decreased drowsiness or sleepiness, which could be undesirable if ketotifen is prescribed specifically for its soporific effects."
"Pseudoephedrine, a sympathomimetic amine, exerts central nervous system (CNS) stimulant effects by indirectly activating adrenergic receptors, which can counteract the sedative properties of ketotifen, a histamine H1-receptor antagonist with mast cell stabilizing activity. This pharmacodynamic antagonism may reduce the therapeutic efficacy of ketotifen in managing allergic conditions, particularly its ability to cause drowsiness as a side effect. Clinically, patients may experience diminished sedation, potentially leading to decreased compliance or altered therapeutic outcomes in conditions where sedation is beneficial."
"Hydroxyamphetamine, an indirect-acting sympathomimetic amine, stimulates the release of norepinephrine from presynaptic nerve terminals, leading to activation of alpha- and beta-adrenergic receptors. This produces central nervous system (CNS) stimulation that may oppose the sedative effects of ketotifen, a histamine H1-receptor antagonist with sedative properties. Consequently, coadministration may result in reduced efficacy of ketotifen for sedation or sleep induction, potentially compromising its therapeutic benefit in conditions requiring CNS depression (e.g., allergic rhinitis, urticaria)."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATARAX vs ACUVUE THERAVISION WITH KETOTIFEN, answered by our medical review team.
ATARAX is a Antihistamine that works by Hydroxyzine is a piperazine derivative with antihistaminic (H1-receptor antagonist) and anticholinergic properties; also exhibits sedative, anxiolytic, and antiemetic effects due to suppression of activity in subcortical areas of the CNS.. ACUVUE THERAVISION WITH KETOTIFEN is a Antihistamine / Mast Cell Stabilizer that works by Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATARAX and ACUVUE THERAVISION WITH KETOTIFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATARAX is: 25 mg orally 3-4 times daily; maximum 100 mg per day. Also available as 50 mg intramuscular injection every 4-6 hours.. The standard adult dose of ACUVUE THERAVISION WITH KETOTIFEN is: One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATARAX and ACUVUE THERAVISION WITH KETOTIFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATARAX is classified as Category C. First trimester: Considered safe; large studies show no increased risk of major malformations. Second trimester: No known specific risks. Third trimester: Use near term may cause n. ACUVUE THERAVISION WITH KETOTIFEN is classified as Category A/B. Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.